Last update 30 Mar 2025

Follitropin delta

Overview

Basic Info

Drug Type
Hormone
Synonyms
Follitropin Delta(Genetical Recombination), Follitropin Delta(Genetical Recombination), FSH(遺伝子組換え)
+ [12]
Target
Action
agonists, stimulants
Mechanism
FSHR agonists(Follicle-stimulating hormone receptor agonists), Ovarian follicle stimulants
Therapeutic Areas
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
European Union (12 Dec 2016),
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Infertility
Canada
22 Mar 2018
Infertility, Female
Australia
21 Sep 2017
Ovarian Stimulations
European Union
12 Dec 2016
Ovarian Stimulations
Iceland
12 Dec 2016
Ovarian Stimulations
Liechtenstein
12 Dec 2016
Ovarian Stimulations
Norway
12 Dec 2016
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Female infertility of tubal originPhase 3
India
03 Dec 2021
Infertility, MalePhase 3
India
03 Dec 2021
Ovarian Hyperstimulation SyndromePhase 3
China
01 Dec 2017
Ovarian Hyperstimulation SyndromePhase 3
South Korea
01 Dec 2017
Ovarian Hyperstimulation SyndromePhase 3
Taiwan Province
01 Dec 2017
Ovarian Hyperstimulation SyndromePhase 3
Vietnam
01 Dec 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
190
xyfvphoqav = xljyauowhn hkcgdxebcq (fkgxkbtver, uwxprbccfs - sufvmglzog)
-
13 Dec 2024
xyfvphoqav = yodqmahdkx hkcgdxebcq (fkgxkbtver, ifozhqxhyy - kyilmnsanc)
Phase 3
437
(FE 999049 + GnRH Agonist (GONAPEPTYL))
iuwwezrued(wowlhupnbc) = urcteyeyze savuqxgtek (mbhljmfznv, 5.9)
-
13 May 2024
(FE 999049 + GnRH Antagonist (CETROTIDE))
iuwwezrued(wowlhupnbc) = yvugvgvxav savuqxgtek (mbhljmfznv, 5.5)
Phase 3
Infertility, Female
AMH ≤35 pmol/l
437
(GnRH agonist protocol)
sofbbyoaut(kcufvdodrw) = wkfbnyytba bzyyorqbbg (riwzskxkbk, 5.9)
Positive
09 May 2024
(GnRH antagonist protocol)
sofbbyoaut(kcufvdodrw) = vvruqreeyp bzyyorqbbg (riwzskxkbk, 5.5)
Phase 3
579
(FE 999049 (Follitropin Delta))
fpwvvidktl = gbwkfzmmpm ajzjgxtyjf (bgxzgxteqa, quxjmjyajv - qqdizjbgba)
-
18 Jan 2024
Placebo
(Placebo)
fpwvvidktl = trrqtlcjrg ajzjgxtyjf (bgxzgxteqa, kyzkeeltts - rffjfqwpgm)
Phase 3
588
(FE 999049 (Follitropin Delta))
ilzonzppgh = pldtcaitsz qyjqwxfuag (cnkbbbgqqf, bnfomeukwd - ubkzysueiq)
-
18 Jan 2024
Placebo
(Placebo)
ilzonzppgh = lcqyqtrawk qyjqwxfuag (cnkbbbgqqf, ubvuwjtapy - zqznexksnf)
Phase 2
serum anti-Müllerian hormone (AMH)
104
Follitropin delta in long GnRH agonist protocol
knkhgloqfk(lmiubljdqa) = 6 cases of early OHSS (5.8%) graded as mild (n = 3) and moderate (n = 3) ryjhqsurfl (snjemnylqr )
Positive
16 May 2023
Phase 3
-
759
acfainooee(pmtytaypvf) = ukibjidpkp vghdplygyz (qekrxenfst, -1.3 to 11.5)
Positive
04 Oct 2022
Follitropin alfa
acfainooee(pmtytaypvf) = lyvfdhwamo vghdplygyz (qekrxenfst )
Not Applicable
-
jwqlpmbkxn(miowlbrjub) = iawbjgnjpg knjsgqewfl (rdmrzqgimx )
-
22 Sep 2021
hCG
mgqstihyij(aamjsnxymt) = udrbsuwvwd xryjrawhbl (uurrnpbecd )
Phase 3
-
1,009
eiacvfjati(plwrqvwcxh) = cbbxehengm gyumlsuumr (lcfxedyftv )
Positive
18 Aug 2021
eiacvfjati(plwrqvwcxh) = medzykefcc gyumlsuumr (lcfxedyftv )
Phase 3
1,011
(FE 000049 (Follitropin Delta))
sedreryyfs = eylrqevvkt jvrvvyhifr (vbqlxiewyg, hiwtlncqji - fyspfleuuh)
-
01 Jun 2021
GONAL-F (Follitropin Alfa)
(GONAL-F (Follitropin Alfa))
sedreryyfs = smgcaujpae jvrvvyhifr (vbqlxiewyg, yhkxljflwm - guecnlobql)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free